These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 37392012)

  • 1. Harnessing placebo: Lessons from psychedelic science.
    Pronovost-Morgan C; Hartogsohn I; Ramaekers JG
    J Psychopharmacol; 2023 Sep; 37(9):866-875. PubMed ID: 37392012
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Self-blinding citizen science to explore psychedelic microdosing.
    Szigeti B; Kartner L; Blemings A; Rosas F; Feilding A; Nutt DJ; Carhart-Harris RL; Erritzoe D
    Elife; 2021 Mar; 10():. PubMed ID: 33648632
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Psychedelics, placebo effects, and set and setting: Insights from common factors theory of psychotherapy.
    Gukasyan N; Nayak SM
    Transcult Psychiatry; 2022 Oct; 59(5):652-664. PubMed ID: 33499762
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expectancy in placebo-controlled trials of psychedelics: if so, so what?
    Butler M; Jelen L; Rucker J
    Psychopharmacology (Berl); 2022 Oct; 239(10):3047-3055. PubMed ID: 36063208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Psychedelic-assisted therapy for treating anxiety, depression, and existential distress in people with life-threatening diseases.
    Schipper S; Nigam K; Schmid Y; Piechotta V; Ljuslin M; Beaussant Y; Schwarzer G; Boehlke C
    Cochrane Database Syst Rev; 2024 Sep; 9(9):CD015383. PubMed ID: 39260823
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blinding and expectancy confounds in psychedelic randomized controlled trials.
    Muthukumaraswamy SD; Forsyth A; Lumley T
    Expert Rev Clin Pharmacol; 2021 Sep; 14(9):1133-1152. PubMed ID: 34038314
    [No Abstract]   [Full Text] [Related]  

  • 7. Set and setting, psychedelics and the placebo response: An extra-pharmacological perspective on psychopharmacology.
    Hartogsohn I
    J Psychopharmacol; 2016 Dec; 30(12):1259-1267. PubMed ID: 27852960
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modalities of the psychedelic experience: Microclimates of set and setting in hallucinogen research and culture.
    Hartogsohn I
    Transcult Psychiatry; 2022 Oct; 59(5):579-591. PubMed ID: 35818775
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In the new era of psychedelic assisted therapy: A systematic review of study methodology in randomized controlled trials.
    Soliman PS; Curley DE; Capone C; Eaton E; Haass-Koffler CL
    Psychopharmacology (Berl); 2024 Jun; 241(6):1101-1110. PubMed ID: 38683460
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Psychosis and psychedelics: Historical entanglements and contemporary contrasts.
    Friesen P
    Transcult Psychiatry; 2022 Oct; 59(5):592-609. PubMed ID: 36300247
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The renaissance in psychedelic research: What do preclinical models have to offer.
    Murnane KS
    Prog Brain Res; 2018; 242():25-67. PubMed ID: 30471682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative oral monotherapy of psilocybin, lysergic acid diethylamide, 3,4-methylenedioxymethamphetamine, ayahuasca, and escitalopram for depressive symptoms: systematic review and Bayesian network meta-analysis.
    Hsu TW; Tsai CK; Kao YC; Thompson T; Carvalho AF; Yang FC; Tseng PT; Hsu CW; Yu CL; Tu YK; Liang CS
    BMJ; 2024 Aug; 386():e078607. PubMed ID: 39168500
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overcoming blinding confounds in psychedelic randomized controlled trials using biomarker driven causal mediation analysis.
    Muthukumaraswamy SD
    Expert Rev Clin Pharmacol; 2023; 16(12):1163-1173. PubMed ID: 37947758
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Great Expectations: recommendations for improving the methodological rigor of psychedelic clinical trials.
    Aday JS; Heifets BD; Pratscher SD; Bradley E; Rosen R; Woolley JD
    Psychopharmacology (Berl); 2022 Jun; 239(6):1989-2010. PubMed ID: 35359159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Psychedelics and the essential importance of context.
    Carhart-Harris RL; Roseman L; Haijen E; Erritzoe D; Watts R; Branchi I; Kaelen M
    J Psychopharmacol; 2018 Jul; 32(7):725-731. PubMed ID: 29446697
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ethical and Practical Considerations for the Use of Psychedelics in Psychiatry.
    Barber GS; Dike CC
    Psychiatr Serv; 2023 Aug; 74(8):838-846. PubMed ID: 36987705
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Psychedelic medicine at a crossroads: Advancing an integrative approach to research and practice.
    Gobbi G; Inserra A; Greenway KT; Lifshitz M; Kirmayer LJ
    Transcult Psychiatry; 2022 Oct; 59(5):718-724. PubMed ID: 36263521
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expectancy Effects in Psychedelic Trials.
    Szigeti B; Heifets BD
    Biol Psychiatry Cogn Neurosci Neuroimaging; 2024 May; 9(5):512-521. PubMed ID: 38387698
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Psychedelic Therapy: A Primer for Primary Care Clinicians-Historical Perspective and Overview.
    Tabaac BJ; Shinozuka K; Arenas A; Beutler BD; Cherian K; Evans VD; Fasano C; Muir OS
    Am J Ther; 2024 Mar-Apr 01; 31(2):e97-e103. PubMed ID: 38518266
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Culture, context, and ethics in the therapeutic use of hallucinogens: Psychedelics as active super-placebos?
    Dupuis D; Veissière S
    Transcult Psychiatry; 2022 Oct; 59(5):571-578. PubMed ID: 36263513
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.